Celldex: Positive Data from Barzolvolimab Phase 1b Study in Urticaria

 - 100% complete response rate in cold urticaria after single dose of barzolvolimab at 1.5 mg/kg, including in omalizumab refractory patients -

- Long term follow up of patients with chronic inducible urticaria treated at 3.0 mg/kg confirm that barzolvolimab-induced responses and mast cell suppression are durable and linked -
- Company to host webcast conference call on Tuesday, December 6 at 8:00 a.m. ET -

  
Webcast and Conference Call
The Company will host a conference call/webcast to discuss the results today at 8:00 a.m. ET. The event will be webcast live and can be accessed by going to the "Events & Presentations" page under the "Investors & Media" section of the Celldex Therapeutics website at www.celldex.com. The call can also be accessed by dialing (800) 715-9871 (within the United States) or (646) 307-1963 (outside the United States). The conference ID is 4307990.

https://www.biospace.com/article/releases/celldex-therapeutics-presents-positive-data-from-barzolvolimab-phase-1b-study-in-chronic-inducible-urticaria-at-global-urticaria-forum-2022/